1. Scrip

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label

 
• By Mandy Jackson

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Shortness of breath
Tezepelumab cut asthma exacerbations on top of standard-of-care drugs • Source: Shutterstock

Amgen, Inc. and AstraZeneca PLC’s tezepelumab showed significant efficacy in reducing patients’ annualized asthma exacerbation rate regardless of their eosinophil levels in the first detailed set of Phase III data in the treatment of severe uncontrolled asthma. The commercial potential remains unclear, however, since doctors say they are unlikely to switch patients with high eosinophil levels who are served well by existing biologics approved for that population.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.